This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-16 and is reviewed periodically as new material appears.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 5,136 Da | Based on the 44-amino-acid peptide backbone and N-terminal modification. |
| Appearance | White to off-white lyophilized powder | Usually supplied in single-use vials for reconstitution. |
| Solubility | Freely soluble in water; slightly soluble in some organic solvents | Peptide nature supports aqueous reconstitution. |
| Typical storage | 2–8 °C, protected from light | Refrigeration reduces degradation; avoid freezing unless specified. |
| Common analytical method | Reverse-phase high-performance liquid chromatography | Used for identity, purity, and quantification. |
| Synonyms | Tesamorelin, TH9507, GHRH(1-44) analog | Generic descriptors; avoid proprietary names. |
As the solidification rate slows down, however, the area fraction of the particle-rich phase drops indicating an increase in packing efficiency. At the same time, the competitive growth process is taking place, replacing r-crystals with z-crystals. At a certain point nearing the end of the transition zone, the particle-rich phase fraction rises sharply since z-crystals are less efficient at packing particles than r-crystals. The apex of this curve marks the point where only z-crystals are present (SSZ). During steady-state growth, after the maximum particle-rich phase fraction is reached, the efficiency of packing increases as steady-state is achieved. In 2011, researchers at Yale University set out to probe the actual spatial packing of particles within the walls. Using small-angle X-ray scattering (SAXS) they characterized the particle size, shape and interparticle spacing of nominally 32 nm silica suspensions that had been freeze-cast at different speeds. Computer simulations indicated that for this system, the particles within the walls should not be touching but rather separated from one another by thin films of ice. Testing, however, revealed that the particles were, in fact, touching and more than that, they attained a packed morphology that cannot be explained by typical equilibrium densification processes.
You cain’t get a man out by cussin’ him out." In the fall of 1998, Mizell had a heart attack while watching his son Dave coach High Point Andrews High School in a football game against North Davidson High School in Welcome. Four months later, on February 21, 1999, Mizell died at the age of 68 in Kerrville, Texas, where he was visiting his wife's family. In moving to have Mizell's obituary recorded in the Congressional Record, Senator Helms observed, "One doesn’t lose a friend like Wilmer Mizell without experiencing a deep and penetrating sadness." His burial site was the Faith Missionary Alliance Church Cemetery in Winston-Salem.
=== Genetics === Happiness is partly genetically based. Based on twin studies, 50 percent of a given human's happiness level is genetically determined, 10 percent is affected by life circumstances and situation, and a remaining 40 percent of happiness is subject to self-control. Whether emotions are genetically determined or not was studied by David Lykken and Auke Tellegen. They found that up to 80% of the variance in long-term sense of well-being among Minnesotan twins separated at birth was attributable to heredity. The remaining theoretical 20%, however, still leaves room for significant change in thoughts and behavior from environmental/learned sources that should not be understated, and the interpretation of variance in twin studies is controversial, even among clinical psychologists. Individual differences in both overall Eudaimonia, identified loosely with self-control, and in the facets of eudaimonia are inheritable. Evidence from one study supports 5 independent genetic mechanisms underlying the Ryff facets of this trait, leading to a genetic construct of eudaimonia in terms of general self-control, and four subsidiary biological mechanisms enabling the psychological capabilities of purpose, agency, growth, and positive social relations.
Sources: en.wikipedia.org
. It is used as a measure of affinity, with higher values indicating a lower affinity. For the given equation (E = enzyme, S = substrate, P = product), E + S ⟺ k − 1 k 1 E S ⟺ k 2 E + P {\displaystyle E+S{\overset {k_{1}}{\underset {k_{-}{1}}{\Longleftrightarrow }}}ES{\overset {k_{2}}{\Longleftrightarrow }}E+P} k d {\displaystyle k_{d}} would be equivalent to k − 1 / k 1 {\displaystyle k_{-1}/k_{1}} , where k 1 {\displaystyle k_{1}} and k − 1 {\displaystyle k_{-1}} are the rates of the forward and backward reaction, respectively in the conversion of individual E and S to the enzyme substrate complex. Information theory allows for a more quantitative definition of specificity by calculating the entropy in the binding spectrum. The chemical specificity of an enzyme for a particular substrate can be found using two variables that are derived from the Michaelis-Menten equation. k m {\displaystyle k_{m}} approximates the dissociation constant of enzyme-substrate complexes. k c a t {\displaystyle k_{cat}}
The variation in the 14C/12C ratio in different parts of the carbon exchange reservoir means that a straightforward calculation of the age of a sample based on the amount of 14C it contains will often give an incorrect result. There are several other possible sources of error that need to be considered. The errors are of four general types:
The problem of lithium-ion battery safety was recognized even before were first commercially released in 1991. The two main reasons for lithium-ion battery fires and explosions are related to processes on the negative electrode (anode when discharging, cathode when charging). During a normal battery charge lithium ions intercalate into graphite. However, if the charge is too fast or the temperature is too low, lithium metal starts plating on the negative electrode, and the resulting dendrites can penetrate the battery separator, internally short-circuit the cell, and result in high electric current, heating and ignition. In other mechanisms, an explosive reaction between the negative electrode material (LiC6) and the solvent (liquid organic carbonate) occurs even at open circuit, provided that the electrode temperature exceeds a certain threshold above 70 °C. Lithium-ion batteries in the 18650 format or larger may incorporate safety mechanisms such as a current interrupt device (CID) and a positive temperature coefficient (PTC) device. The CID consists of two metal disks in electrical contact. When internal pressure increases, the disks separate, breaking the circuit and terminating the current. The PTC device is composed of a conductive polymer; an increase in current causes the polymer to heat, increasing its electrical resistance and reducing the current flow.
Sources: en.wikipedia.org
=== Medications === Some medications, such as glucocorticoids, cannabinoids, and progestins were initially used in treating cachexia and aim to increase appetite. Progestins showed promise initially, but they do not stop muscle wasting and may cause fluid retention, fat gain, and other side effects. Ghrelin agonists, such as anamorelin are commonly used in cancer treatment to boost appetite, increase weight, and increase muscle mass. However, its use and effectiveness in cachexia is not well studied. Selective androgen receptor modulators (SARMs) such as enobosarm show promise in increasing physical performance and muscle mass, but more studies are needed to confirm their effectiveness in cachexia. The use of anti-inflammatory medications have been investigated. Thalidomide, an anti-inflammatory agent, has shown promise in preventing weight loss, but the use of this medication in cachexia is not widely accepted. However, other TNF inhibitors have not shown the same promising results. NSAIDs such as celecoxib and ibuprofen showed some early benefits, but side effects (renal injury, GI bleeding) limit their use. Anti-nausea drugs such as 5-HT3 antagonists are also commonly used if nausea is a prominent symptom. Anabolic steroids like oxandrolone may help but are only recommended for short term use due to side effects including liver toxicity.
== Derivatives == A variety of 1,4-butanediol derivatives are GHB-like drugs or GHB receptor agonists. These include GHB itself, γ-butyrolactone (GBL), aceburic acid, ethyl acetoxy butanoate (EAB), Γ-crotonolactone, γ-hydroxybutyraldehyde, γ-hydroxyvaleric acid (GHV), γ-valerolactone (GVL), γ-hydroxycrotonic acid (GHC or T-HCA), and 4-hydroxy-4-methylpentanoic acid (UMB68), among others. An analogue that is not a 1,4-butanediol derivative but is related and still shows affinity for the GHB receptor is 3-chloropropanoic acid (UMB66).
== Awards and honors == 1958: Third place in the Westinghouse Science Talent Search (currently called the International Science and Engineering Fair), a prestigious nationwide science fair 1985: MacArthur Fellowship, also called the "Genius Grant" awarded to individuals who have "shown extraordinary originality and dedication in their creative pursuits and marked capacity for self-direction" 1991: Election to National Academy of Science, an honor that recognizes exceptional previous and continual original research 2006: Election to the National Academy of Medicine in Washington, D.C., a nonprofit institution that strives to offer objective science, technology, and health advice 2012: American Crystallographic Association fellow in 2012 for fulfilling the following criteria: "a Member whose efforts on behalf of the advancement of crystallography or its applications that are scientifically or socially distinguished" 2012 - 2013: President of the Biophysical society 2019: Alexander Hollaender Award in Biophysics, an award of distinguished biophysics contributions
== Research == In his academic research, Verdine made fundamental discoveries about how organisms manage their genomes: how they tag specific cell types and conduct search-and-destroy operations for cancer-causing abnormalities. Verdine has published more than 190 academic articles. In 2005, Verdine and Anirban Banerjee published research in crystallography showing how enzymes could be used to fix flawed DNA. In 2013, Verdine received a research grant to study cell-penetrating miniproteins in order to target cancer cells. His work has led to the FDA approval of the drugs romidepsin and paritaprevir. Verdine is also the inventor of stapled peptide technology, which stabilizes peptides intended for therapeutic use by introducing an all-hydrocarbon “staple” into the peptide’s linear backbone. These “stapled” peptides have a higher affinity for their targets, enter cells more easily and are less readily degraded.
Sources: en.wikipedia.org
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.
Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.
Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.